Page 823 - medicina-integrativa_compress

840 PARTE II, SECCIÓN 13 CÁNCER

21. Chung LWK, Baseman A, Assikis V, et al: Molecular insights into Med 165:1005-1010, 2005.
prostate cancer progression: The missing link of tumor 48. Giri VN, Cassidy AE, Beebe-Dimmer J, et al: Association between
microenvironment. J Urol 173:10-20, 2005. Agent Orange and prostate cancer: A pilot case-control study.
22. American Cancer Society: Cancer Reference Information: Urology 63:757-760, 2004.
www.cancer.org/docroot/CRI/content/CRI_2_4_3X_Can_prostate_ 49. Ritchie JM, Vial SL, Fuortes LJ, et al: Organochlorines and risk of
cancer_be_found_early_36.asp/ prostate cancer. J Occup Environ Med 45:692-702, 2003.
23. Carroll P, Coley C, McLeod D, et al: Prostate-specific antigen best 50. Jones JA, Nguyen A, Straub M: Use of DHEA in a patient with
practice policy. Part I: Early detection and diagnosis of prostate advanced prostate cancer: A case report and review. Urology
cancer. Urology 57:217-224, 2001. 50:784-788, 1997.
24. Schröder FH: Screening for prostate cancer. Urol Clin North Am 51. Meyers CD Jr: Chondroitin sulfate. Prostate Forum:
30:239-251, 2003. www.prostateforum.com/september2001.pdf
25. Etzionim E, Legler JM, Feuer EJ, et al: Cancer surveillance series: 52. Putnam SD, Cerhan JR, Parker AS, et al: Lifestyle and
Interpreting trends in prostate cancer. Part III: Quantifying the link anthropometric risk factors for prostate cancer in a cohort of Iowa
between population prostate-specific antigen testing and recent men. Ann Epidemiol 10:361-369, 2000.
declines in prostate cancer mortality. J Natl Cancer Inst 91: 53. Schoonen WM, Salinas CA, Kiemeney LA: Alcohol consumption
1033-1039, 1999. and the risk of prostate cancer in middle aged men. Int J Cancer
26. Horninger W, Berger A, Pelzer A, et al: Screening for prostate 113:133-140, 2005.
cancer: Updated experience from the Tyrol Study. Current Prostate 54. Rodriguez C, Tatham LM, Thun MJ, et al: Smoking and fatal
Reports 3:5-10, 2005. prostate cancer in a large cohort of adult men. Am J Epidemol
27. Fang J, Metter J, Landis P, et al: Low levels of prostate-specific 145:466-475, 1997.
antigen predict long-term risk of prostate cancer: Results from the 55. Giovannucci E, Rimm EB, Colditz GA, et al: A prospective study
Baltimore Longitudinal Study of Aging. Urology 58:411-416, 2001. of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85:
28. Benoit RM, Gronberg H, Naslund MJ: A quantitative analysis of the 1571-1579, 1993.
costs and benefits of prostate cancer screening. Prostate Cancer 56. Kolonel LN, Nomura MY, Cooney RV: Dietary fat and prostate
Prostatic Dis 4:138-145, 2001. cancer: Current status. J Natl Cancer Inst 91:414-428, 1999.
29. Carter B: Rationale for earlier and less frequent prostate cancer 57. Hayes RB, Ziegler RG, Gridley G, et al: Dietary factors and risks for
screening. Urology 58:639-641, 2001. prostate cancer among blacks and whites in the United States.
30. Gann P, Hennekens C, Stampfer M: A prospective evaluation of Cancer Epidemiol Biomarkers Prev 8:25-34, 1999.
plasma prostate-specific antigen for detection of prostate cancer. 58. Ghosh J, Myers CE: Arachidonic acid metabolism and cancer of the
JAMA 273:289-294, 1995. prostate. Nutrition 14:48-49, 1998.
31. Schroeder FH: The European Screening Study for Prostate Cancer. 59. Hakim I: Mediterranean diets and cancer prevention. Arch Intern
Can J Oncol 4:102-105, 1994. Med 158:1169-1170, 1998.
32. Woolf SH: Prostate cancer screening in the prostate, lung, colorectal, 60. Schulman CC, Ekane S, Zlotta AR: Nutrition and prostate cancer:
and ovarian screening trial of the National Cancer Institute. J Urol Evidence or suspicion? Urology 58:318-334, 2001.
152:1905-1909, 1994. 61. Moyad MA: Dietary fat reduction to reduce prostate cancer risk:
33. Carter HB, Partin AW: Diagnosis and staging of prostate cancer. In Controlled enthusiasm, learning a lesson from breast or other
Walsh PC, Retik AB, Vaughan ED Jr, et al (eds): Campbell’s cancers, and the big picture. Urology 59:51-62, 2002.
Urology, 8th ed. Philadelphia, WB Saunders, 2002, pp 3055-3079. 62. Mukherjee P, Sotnikov AV, Manigian HJ, et al: Energy intake and
34. Richardson TD, Oesterling JE: Age-specific reference ranges prostate tumor growth: Angiogenesis and vascular endothelial
for serum prostate-specific antigen. Urol Clin North Am 24: growth factor expression. J Natl Cancer Inst 91:512-522, 1999.
339-351, 1997. 63. Castle EP, Thrasher JB: The role of soy phytoestrogens in prostate
35. Catalona WJ, Partin AW, Slawin KM, et al: Use of percentage of free cancer. Urol Clin North Am 29:71-81, 2002.
prostate-specific antigen to enhance differentiation of prostate 64. Aldercreutz H, Markkanen H, Watanabe S: Plasma concentration of
cancer from benign prostatic disease. JAMA 279:1542-1547, 1998. phytoestrogens in Japanese men. Lancet 342:1209-1210, 1993.
36. Klein LT, Lowe FC: The effects of prostatic manipulation on prostate- 65. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC: Production
specific antigen levels. Urol Clin North Am 24:293-297, 1997. and actions of estrogens. N Engl J Med 346:340-352, 2002.
37. Fang J, Metter EJ, Landis P, et al: PSA velocity for assessing prostate 66. Jacobsen BK, Knutsen SF, Fraser GE: Does high soymilk intake
cancer risk in men with PSA levels between 2.0 and 4.0 ng/mL. reduce prostate cancer incidence? The Adventist Health Study
Urology 59:889-893, 2002. (United States). Cancer Causes Control 9:553-557, 1998.
38. Babaian RJ, Johnston DA, Naccarato W, et al: The incidence of 67. Hussain M, Banerjee M, Sarkar FH, et al: Soy isoflavones in the
prostate cancer in a screening population with a serum prostate treatment of prostate cancer. Nutr Cancer 47:111-117, 2003.
specific antigen between 2.5 and 4.0 ng/ml: Relation to biopsy 68. Miller EC, Giovannucci E, Erdman JW, et al: Tomato products,
strategy. J Urol 165:757-760, 2001. lycopene, and prostate cancer risk. Urol Clin North Am 29:83-93,
39. Gilbert SM, Cavallo CB, Kahane H, et al: Evidence suggesting PSA 2002.
cutpoint of 2.5 ng/mL for prompting prostate biopsy: Review of 69. Ansari MS, Gupta NP: Lycopene: A novel drug therapy in hormone
36,316 biopsies. Urology 65:549-553, 2005. refractory metastatic prostate cancer. Urol Oncol 22:415-20, 2004.
40. Horninger W, Volgger H, Rogarsch H, et al: Consideration of low 70. Hwang E-S, Bowen PE: Can the consumption of tomatoes or
PSA cut off levels to optimize the detection of curable prostate lycopene reduce cancer risk? Integr Cancer Ther 1:121-132, 2002.
cancer. Eur Urol 39(Suppl 4):43-46, 2001. 71. Giovannucci E, Ascherio A, Rimm EB, et al: Intake of carotenoids
41. Block KI: Integrative tumor board: Recently diagnosed prostate and retino in relation to risk of prostate cancer. J Natl Cancer Inst
cancer. Integr Cancer Ther 2:63-90, 2003. 87:1767-1776, 1995.
42. Ornish D, Weidner G, Fair WR, et al: Intensive lifestyle changes may 72. Cohen JH, Kristal AR, Stanford JL: Fruit and vegetable intakes and
affect the progression of prostate cancer. J Urol 174:1065-1070, 2005. prostate cancer risk. J Natl Cancer Inst 92:61-68, 2000.
43. Vita AJ, Terry RB, Hubert HB, Fries JF: Aging, health risks, and 73. Heinonen OP, Albanes D, Virtamo J, et al: Prostate cancer and
cumulative disability. N Engl J Med 338:1035-1041, 1998. supplementation with alpha-tocopherol and beta-carotene: Incidence
44. Moyad MA: Emphasizing and promoting overall health and and mortality in a controlled trial. J Natl Cancer Inst 90:440-446, 1998.
nontraditional treatments after a prostate cancer diagnosis. Semin 74. Fleshner NE: Vitamin E and prostate cancer. Urol Clin North Am
Urol Oncol 17:119-124, 1999. 29:107-113, 2002.
45. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like 75. Jellin JM: Pharmacist’s Letter/Prescriber’s Letter Natural Medicines
growth factor-1 and prostate cancer risk: A prospective study. Comprehensive Database, 7th ed. Stockton, Calif, Therapeutic
Science 279:563-566, 1998. Research Faculty, 2005, p 1372.
46. Whittemore AS, Kolonel LN, Wu AH, et al: Prostate cancer in relation 76. Clark LC, Combs GF Jr, Turnbull BW, et al: Effects of selenium
to diet, physical activity, and body size in blacks, whites and Asians in supplementation for cancer prevention in patients with carcinoma
the United States and Canada. J Natl Cancer Inst 87:652-661, 1995. of the skin. JAMA 276:1957-1963, 1996.
47. Giovannucci EL, Liu Y, Leitzmann MF, et al: A prospective study of 77. Klein EA: Selenium: Epidemiology and basic science. J Urol 171:
physical activity and incident and fatal prostate cancer. Arch Intern S50-S53, 2004.